Randomized Trialhigh evidence
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial.
Journal of hepatology·March 25, 2026·PMID 41895606
Why it mattersThis study provides granular, AI-quantified evidence that resmetirom not only improves categorical fibrosis stages but also reduces specific collagen features linked to disease progression. It supports resmetirom’s antifibrotic mechanism and highlights digital pathology as a sensitive tool for assessing treatment response in MASH.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled